Ticker > Company >

Sotac Pharmaceutical share price

Sotac Pharmaceuticals Ltd.

NSE: SOTAC SECTOR: Pharmaceuticals & Drugs  11.63 K   41   2

123.40
0 0
NSE: Today, 10:57 AM

Price Summary

Today's High

₹ 0

Today's Low

₹ 0

52 Week High

₹ 152.35

52 Week Low

₹ 88.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

136.36 Cr.

Enterprise Value

156.04 Cr.

No. of Shares

1.11 Cr.

P/E

28.58

P/B

2.57

Face Value

₹ 10

Div. Yield

0.08 %

Book Value (TTM)

₹  47.99

CASH

0.45 Cr.

DEBT

20.13 Cr.

Promoter Holding

72.85 %

EPS (TTM)

₹  4.32

Sales Growth

-7.03%

ROE

9.42 %

ROCE

11.44%

Profit Growth

-17 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-7.03%
3 Year-5.17%
5 Year16.88%

Profit Growth

1 Year-17%
3 Year13.13%
5 Year46.53%

ROE%

1 Year9.42%
3 Year25.65%
5 Year31.58%

ROCE %

1 Year11.44%
3 Year20.16%
5 Year23.69%

Debt/Equity

0.3796

Price to Cash Flow

-22.42

Interest Cover Ratio

6.4718

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 72.85 0.00
Mar 2025 72.85 0.00
Sep 2024 72.85 0.00
Mar 2024 72.85 0.00
Sep 2023 72.85 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 25.6462666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 20.1589333333333% over the past 3 years.
  • Company has a healthy liquidity position with current ratio of 2.0721.
  • The company has a high promoter holding of 72.85%.

 Limitations

  • The company has shown a poor revenue growth of -5.16900818105843% for the Past 3 years.
  • Company has negative cash flow from operations of -6.082.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Dec 2023 Jun 2024
Net Sales 18.91 17.68 13.01
Total Expenditure 16.65 14.75 10.91
Operating Profit 2.26 2.93 2.1
Other Income 0.23 0.27 0.43
Interest 0.34 0.23 0.26
Depreciation 0.46 0.68 0.6
Exceptional Items 0 -0.23 0
Profit Before Tax 1.69 2.06 1.67
Tax 0.48 0.57 0.42
Profit After Tax 1.2 1.49 1.25
Adjusted EPS (Rs) 1.09 1.35 1.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 43.44 73.15 57.98 67.11 62.38
Total Expenditure 40.64 66.96 49.74 57.13 54.7
Operating Profit 2.8 6.19 8.25 9.97 7.69
Other Income 0.08 0.21 0.24 1.32 2.38
Interest 0.56 0.59 0.9 1.02 1.17
Depreciation 1.12 1.13 1.63 2.51 2.47
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.21 4.69 5.96 7.76 6.41
Tax 0.34 1.39 1.47 2.01 1.64
Net Profit 0.86 3.3 4.5 5.75 4.77
Adjusted EPS (Rs.) 1.07 4.09 5.58 5.2 4.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 2.3 2.3 8.05 11.05 11.05
Total Reserves 1.92 4.8 12.94 37.22 41.98
Borrowings 2.72 0.97 6.59 4.41 5.63
Other N/C liabilities 0.06 0.17 0.04 0 -0.06
Current liabilities 14.91 28.06 27.11 23.28 26.49
Total Liabilities 21.91 36.3 54.74 75.96 85.1
Assets
Net Block 6.42 8.8 14.09 17.67 16.66
Capital WIP 0 0 0.04 0.05 0.2
Intangible WIP 0 0 0 0 0
Investments 2.17 0 4 11.5 13.33
Loans & Advances 0.16 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 13.15 27.5 36.61 46.75 54.9
Total Assets 21.91 36.3 54.74 75.96 85.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1.21 4.69 5.96 7.76 6.41
Adjustment 1.6 2.94 2.38 0.21 2.09
Changes in Assets & Liabilities -0.03 -2.62 1.87 -26.02 -13.78
Tax Paid -0.42 -1.43 -1.68 -1.69 -0.8
Operating Cash Flow 2.35 3.58 8.54 -19.75 -6.08
Investing Cash Flow -1.2 -3.28 -10.93 -12.53 -1.89
Financing Cash Flow -1.17 -0.3 11.97 23.32 7.78
Net Cash Flow -0.02 0 9.57 -8.96 -0.2

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Mar 2024% Sep 2024% Mar 2025% Sep 2025%
promoters 72.85 72.85 72.85 72.85 72.85
chetankumar bachubhai pat... 9.68 9.68 9.68 9.68 9.68
dhara chetankumar patel 0.16 0.16 0.16 0.16 0.16
dineshkumar babulal gelot... 12.95 12.95 12.95 12.95 12.95
kiran baldevbhai jotania 13.11 13.11 13.11 13.11 13.11
mitul shaileshkumar patel... 3.28 3.28 3.28 3.28 3.28
pinki sharadkumar patel 0.16 0.16 0.16 0.16 0.16
sarojben dineshkumar gelo... 0.16 0.16 0.16 0.16 0.16
shaileshkumar vishnuprasa... 7.29 7.29 7.29 7.29 7.29
sharadkumar dashrathbhai ... 12.95 12.95 12.95 12.95 12.95
vasantkumar devrajbhai pa... 0.16 0.16 0.16 0.16 0.16
vishalkumar devrajbhai pa... 12.95 12.95 12.95 12.95 12.95
PARTICULARS Sep 2023% Mar 2024% Sep 2024% Mar 2025% Sep 2025%
investors 27.15 27.15 27.15 27.15 27.15
craft emerging market fun... - - - - 6.95
minerva ventures fund 1.64 1.64 1.64 1.64 1.64
nav capital vcc - nav cap... 5.98 7.30 7.24 7.09 7.09
sambhavnath investments a... 2.85 3.18 2.91 - 1.93
walpar nutritions limited... 1.49 1.49 1.49 1.49 1.49
craft emerging market fun... - - - 6.39 -
sambhavnath investments a... - - - 1.77 -
goenka business and finan... 4.59 3.96 3.55 - -
v joshi impex private lim... - - 1.37 - -

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Sotac Pharmaceutical Stock Price Analysis and Quick Research Report. Is Sotac Pharmaceutical an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sotac Pharmaceutical. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sotac Pharmaceutical has a PE ratio of 28.5760600236204 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sotac Pharmaceutical has ROA of 5.9256% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sotac Pharmaceutical has a Current ratio of 2.0721.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sotac Pharmaceutical has a ROE of 9.4206%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sotac Pharmaceutical has a Debt to Equity ratio of 0.3796 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sotac Pharmaceutical has reported revenue growth of -7.0349% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sotac Pharmaceutical for the current financial year is 12.3193052086907%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sotac Pharmaceutical is Rs 0.1 and the yield is 0.081%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sotac Pharmaceutical is Rs 4.3183. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sotac Pharmaceutical in Ticker for free. Also, one can get the intrinsic value of Sotac Pharmaceutical by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sotac Pharmaceutical FAQs

Q1. What is Sotac Pharmaceutical share price today?
Ans: The current share price of Sotac Pharmaceutical is Rs 123.4.

Q2. What is the market capitalisation of Sotac Pharmaceutical?
Ans: Sotac Pharmaceutical has a market capitalisation of Rs 136.357 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sotac Pharmaceutical?
Ans: The PE ratio of Sotac Pharmaceutical is 28.5760600236204 and the P/B ratio of Sotac Pharmaceutical is 2.5713476028539, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sotac Pharmaceutical share?
Ans: The 52-week high share price of Sotac Pharmaceutical is Rs 152.35, and the 52-week low share price of Sotac Pharmaceutical is Rs 88.05.

Q5. Does Sotac Pharmaceutical pay dividends?
Ans: Currently, Sotac Pharmaceutical pays dividends. Dividend yield of Sotac Pharmaceutical is around 0.081%.

Q6. What are the face value and book value of Sotac Pharmaceutical shares?
Ans: The face value of Sotac Pharmaceutical shares is Rs 10, while the book value per share of Sotac Pharmaceutical is around Rs 47.9904. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sotac Pharmaceutical?
Ans: Sotac Pharmaceutical has a total debt of Rs 20.1278 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sotac Pharmaceutical?
Ans: The ROE of Sotac Pharmaceutical is 9.4206% and ROCE of Sotac Pharmaceutical is 11.4426%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sotac Pharmaceutical a good buy for the long term?
Ans: The Sotac Pharmaceutical long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sotac Pharmaceutical undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sotac Pharmaceutical appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sotac Pharmaceutical’s financials?
Ans: You can review Sotac Pharmaceutical’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sotac Pharmaceutical
X